Showing 1261-1270 of 5771 results for "".
- WAVE Eye Care Announces New Integration Between Topcon MYAH and WAVE Lens Designer Softwarehttps://modernod.com/news/wave-eye-care-announces-new-integration-between-topcon-myah-and-wave-lens-designer-software/2485329/At the Global Specialty Lens Symposium (GSLS) in Las Vegas, WAVE Eye Care announced a integration between the Topcon MYAH and WAVE Lens Designer Software designed to streamline the specialty contact lens fitting and design process for eye care practitioners.
- Topcon Healthcare and RemoniHealth Announce Strategic Partnership to Advance Remote Eye Carehttps://modernod.com/news/topcon-healthcare-and-remonihealth-announce-strategic-partnership-to-advance-remote-eye-care/2485306/Topcon Healthcare announced a new commercial partnership with RemoniHealth, a provider of remote care management and AI-enabled ocular disease monitoring. According to Topcon, the collaboration advances the company's tele-ey
- Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunthttps://modernod.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.
- 4DMT and Otsuka Announce Strategic Partnership to Advance 4D-150 Gene Therapy Across Asia-Pacifichttps://modernod.com/news/4dmt-and-otsuka-announce-strategic-partnership-to-advance-4d-150-gene-therapy-across-asia-pacific/2484301/4D Molecular Therapeutics (4DMT) announced a strategic partnership with Otsuka Pharmaceutical to develop and commercialize 4D-150 for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) across the greater Asia-Pacific (
- Novartis Announces Positive Phase 3 Results for Ianalumab in Sjögren’s Diseasehttps://modernod.com/news/novartis-announces-positive-phase-3-results-for-ianalumab-in-sjogrens-disease/2484297/Novartis announced new late-breaking data from the NEPTUNUS-1 and NEPTUNUS-2 phase 3 trials evaluating ianalumab in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease. The results, presented during the American College of Rheumatol
- Locus Biosciences Announces Collaboration with Viatris to Develop Antibacterial Therapies for Ophthalmic Infectionshttps://modernod.com/news/locus-biosciences-announces-collaboration-with-viatris-to-develop-antibacterial-therapies-for-ophthalmic-infections/2484292/Locus Biosciences announced a research collaboration agreement with Viatris to develop novel engineered bacteriophage therapies targeting ophthalmic bacterial infections. While financial terms of the deal were not disc
- Nanoscope Announces 3-Year Vision Improvements from REMAIN Study of MCO-010 in RPhttps://modernod.com/news/nanoscope-announces-3-year-vision-improvements-from-remain-study-of-mco-010-in-retinitis-pigmentosa/2484207/Nanoscope Therapeutics announced 3-year follow-up data from the REMAIN study, the long-term extension of its pivotal phase 2b/3 RESTORE trial evaluating MCO-010, the company’s proprietary optogenetic therapy for retinitis pigmentosa (RP).
- Ophthalmic World Leaders (OWL) Announces 2025 Leadership Award Honoreeshttps://modernod.com/news/ophthalmic-world-leaders-owl-announces-2025-leadership-award-honorees/2484206/Ophthalmic World Leaders (OWL) announced its 2025 Leadership Award honorees, leaders who are shaping the future of eyecare through innovation, inclusion, and impact. The 2025 OWL Award recipients:
- Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progressionhttps://modernod.com/news/astellas-announces-new-data-demonstrating-long-term-efficacy-of-izervay-in-slowing-ga-progression/2484199/Astellas Pharma announced the first results from the open-label extension (OLE) trial of the phase 3 GATHER2 study, which showed that monthly treatment with Izervay (avacincaptad pegol intravitreal solution) continued to slow disease progression in patie
- Aurion Announces Positive 12-Month Results from Phase 1/2 CLARA Trial of AURN001 Corneal Endothelial Cell Therapyhttps://modernod.com/news/aurion-announces-positive-12-month-results-from-phase-12-clara-trial-of-aurn001-corneal-endothelial-cell-therapy/2484196/Aurion Biotech announced positive 12-month results from its phase 1/2 CLARA clinical trial. The study evaluated the safety, efficacy, and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor)